Cell Signaling Technology

Product Pathways - Apoptosis

SignalSilence® Mcl-1 siRNA I #6315

Applications Reactivity
Transfection H

Reactivity Key:  H=Human
Species cross-reactivity is determined by western blot. Species enclosed in parentheses are predicted to react based on 100% sequence homology.

Western Blotting

Western Blotting

Western blot analysis of extracts from HeLa cells, transfected with 100 nM SignalSilence® Control siRNA (Unconjugated) #6568 (-) or SignalSilence® Mcl-1 siRNA I (+), using Mcl-1 (D35A5) Rabbit mAb #5453 (upper) or α-Tubulin (11H10) Rabbit mAb #2125 (lower). The Mcl-1 (D35A5) Rabbit mAb confirms silencing of Mcl-1 expression, while the α-Tubulin (11H10) Rabbit mAb is used as a loading control.

Description

SignalSilence® Mcl-1 siRNA I from Cell Signaling Technology (CST) allows the researcher to specifically inhibit Mcl-1 expression using RNA interference, a method whereby gene expression can be selectively silenced through the delivery of double stranded RNA molecules into the cell. All SignalSilence® siRNA products from CST are rigorously tested in-house and have been shown to reduce target protein expression by western analysis.

Quality Control

Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.

Directions for Use

CST recommends transfection with 100 nM Mcl-1 siRNA I 48 to 72 hours prior to cell lysis. For transfection procedure, follow protocol provided by the transfection reagent manufacturer. Please feel free to contact CST with any questions on use.

Each vial contains the equivalent of 100 transfections, which corresponds to a final siRNA concentration of 100 nM per transfection in a 24-well plate with a total volume of 300 μl per well.

Background

Mcl-1 is an anti-apoptotic member of the Bcl-2 family originally isolated from the ML-1 human myeloid leukemia cell line during phorbol ester-induced differentiation along the monocyte/macrophage pathway (1). Similar to other Bcl-2 family members, Mcl-1 localizes to the mitochondria (2), interacts with and antagonizes pro-apoptotic Bcl-2 family members (3), and inhibits apoptosis induced by a number of cytotoxic stimuli (4). Mcl-1 differs from its other family members in its regulation at both the transcriptional and post-translational level. First, Mcl-1 has an extended amino-terminal PEST region, which is responsible for its relatively short half-life (1,2). Second, unlike other family members, Mcl-1 is rapidly transcribed via a PI3K/Akt dependent pathway, resulting in its increased expression during myeloid differentiation and cytokine stimulation (1,5-7). Mcl-1 is phosphorylated in response to treatment with phorbol ester, microtubule-damaging agents, oxidative stress, and cytokine withdrawal (8-11). Phosphorylation at Thr163, the conserved MAP kinase/ERK site located within the PEST region, slows Mcl-1 protein turnover (10) but may prime the GSK-3 mediated phosphorylation at Ser159 that leads to Mcl-1 destabilization (11). Mcl-1 deficiency in mice results in peri-implantation lethality (12). In addition, conditional disruption of the corresponding mcl-1 gene shows that Mcl-1 plays an important role in early lymphoid development and in the maintenance of mature lymphocytes (13).

  1. Kozopas, K.M. et al. (1993) Proc Natl Acad Sci USA 90, 3516-20.
  2. Yang, T. et al. (1995) J Cell Biol 128, 1173-84.
  3. Sato, T. et al. (1994) Proc Natl Acad Sci USA 91, 9238-42.
  4. Zhou, P. et al. (1997) Blood 89, 630-43.
  5. Wang, J.M. et al. (1999) Mol Cell Biol 19, 6195-206.
  6. Jourdan, M. et al. (2003) Oncogene 22, 2950-9.
  7. Chao, J.R. et al. (1998) Mol Cell Biol 18, 4883-98.
  8. Domina, A.M. et al. (2000) J Biol Chem 275, 21688-94.
  9. Inoshita, S. et al. (2002) J Biol Chem 277, 43730-4.
  10. Domina, A.M. et al. (2004) Oncogene 23, 5301-15.
  11. Maurer, U. et al. (2006) Mol Cell 21, 749-60.
  12. Rinkenberger, J.L. et al. (2000) Genes Dev 14, 23-7.
  13. Opferman, J.T. et al. (2003) Nature 426, 671-6.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

Limited Use Label License, RNA interference: This product is licensed under European Patent 1144623 and foreign equivalents from Ribopharma AG, Kulmbach, Germany and is provided only for use in non-commercial research specifically excluding use (a) in drug discovery or drug development, including target identification or target validation, by or on behalf of a commercial entity, (b) for contract research or commercial screening services, (c) for the production or manufacture of siRNA-related products for sale, or (d) for the generation of commercial databases for sale to Third Parties. Information about licenses for these and other commercial uses is available from Ribopharma AG, Fritz-Hornschuch-Str. 9, D-95326 Kulmbach, Germany.

For Research Use Only. Not For Use In Diagnostic Procedures.

Products